1. Home
  2. KZR vs INCR Comparison

KZR vs INCR Comparison

Compare KZR & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kezar Life Sciences Inc.

KZR

Kezar Life Sciences Inc.

HOLD

Current Price

$7.29

Market Cap

54.2M

Sector

Health Care

ML Signal

HOLD

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$1.21

Market Cap

47.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KZR
INCR
Founded
2015
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.2M
47.4M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
KZR
INCR
Price
$7.29
$1.21
Analyst Decision
Hold
Analyst Count
4
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
118.8K
20.2K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$69.54
Revenue Next Year
N/A
$41.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.53
$0.68
52 Week High
$7.55
$1.77

Technical Indicators

Market Signals
Indicator
KZR
INCR
Relative Strength Index (RSI) 54.64 80.31
Support Level $7.25 $0.72
Resistance Level $7.47 $1.68
Average True Range (ATR) 0.11 0.05
MACD -0.02 0.03
Stochastic Oscillator 37.50 95.12

Price Performance

Historical Comparison
KZR
INCR

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Share on Social Networks: